Skip to main content
. 2022 Oct 4;192(2):205–216. doi: 10.1093/aje/kwac170

Figure 1.

Figure 1

Cumulative numbers of recombinant zoster vaccine (RZV) doses administered in a Vaccine Safety Datalink study cohort, by 10-year age group (A) and study site (B), January 2018–December 2019. (Study sites 1–7 cannot be identified because of data privacy concerns.)